New compounds aim to strengthen weakened hearts

New therapies developed by pharmaceutical company Bayer are helping to prevent heart failure among those who got weak hearts.

Statistics show one in five people suffer from heart failure during the course of their lives.

In Germany alone, more than 40,000 deaths per year are caused by a weak heart.

The new therapies are designed to strengthen the body's most important muscle and can potentially improve the quality of life of those affected and reduce hospital admissions and deaths.

The heart has been painted by artists, described by poets and extolled by bards, and yet it is merely a 300-gram collection of blood vessels and muscle tissue.

Through a network of arteries, veins and tiny capillaries, the heart pumps up to 10,000 liters of blood through the circulatory system every day, keeping the human system running. It is a perfect construction, but one that is prone to failure.

According to estimates by the German Heart Foundation, around 2.5 million people in Germany suffer from cardiac insufficiency, or chronic heart failure.

Their heart muscle is no longer able to transport enough oxygen and nutrients to organs, tissues and cells.

A gradual process

Other than the occasional cold, Peter Christensen had never been seriously ill. As a self-employed civil engineer, he often sat at his desk until late in the evening and was used to exertion.

As a keen tennis player, he often pushed himself to the limit. "But after my 65th birthday, I gradually lost my strength," he recalls.

First, he struggled for breath on the tennis court, and then climbing the stairs to his office in Duesseldorf's historic district left him gasping for air.

"I blamed it on age and all the stress," says the now 72-year-old. But his cardiologist diagnosed advanced heart failure, caused by the high blood pressure Christensen had ignored for years.

Heart failure often creeps slowly into the lives of those affected. "It develops over months or even years," explains professor Burkert Pieske, director of Clinics for Internal Medicine and Cardiology at Charité Berlin and the German Heart Institute Berlin.

"Those affected are short of breath, their performance decreases, or they suffer from water retention－edema," says the cardiologist, summing up the most common symptoms.

According to the German Heart Report, chronic heart failure is one of the most common causes of death in Germany, affecting 40,300 people, and is the main reason for hospitalization, accounting for more than 460,000 cases per year.

This is because many sufferers fail to recognize the symptoms and wait too long before seeking medical help. However, the earlier therapy begins, the longer the life expectancy.

More affected people

Strictly speaking, cardiac insufficiency is not a disease in its own right, but usually the result of an underlying condition.

According to the German Heart Foundation, in about two-thirds of cases it is caused by constricted coronary arteries or occurs after a heart attack; in other patients it is caused by inflammation of the heart muscle, defective heart valves or genetic factors.

Alcohol and drug consumption, medications, rheumatic disorders or diabetes also affect the heart and can lead to insufficiency.

In fact, the list of possible causes is long. In our aging society, a weak heart is a growing problem.

According to a study by the George Institute for Global Health in Oxford, up to 5 percent of 65- to 75-year-olds and almost 10 percent of those over 80 already suffer from it. Within two years, the number of people affected has risen by 3.7 percent, according to the German Heart Foundation.

A reversal of the trend is not in sight. Medical progress is helping many heart patients to live longer, even if their most important organ is already severely weakened.

"We now have a whole range of drugs that improve the quality of life of those affected and reduce hospital admissions and the number of deaths," says Pieske.

This story has been published in the German newspaper Handelsblatt and provided by Bayer.